ATE406892T1 - Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil - Google Patents

Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil

Info

Publication number: ATE406892T1
Authority: AT; Austria
Prior art keywords: gemcitabine; uracil; fluoro; preparations containing; combination preparations
Prior art date: 2001-04-06

Application number

AT02726710T

Other languages

English (en)

Inventor

James Gibbons

Gary Dukart

Jurgen Frisch

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-06

Filing date

2002-04-05

Publication date

2008-09-15

2002-04-05 Application filed by Wyeth Corp filed Critical Wyeth Corp

2008-09-15 Application granted granted Critical

2008-09-15 Publication of ATE406892T1 publication Critical patent/ATE406892T1/de

Links

GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 title abstract 2
229960002949 fluorouracil Drugs 0.000 title abstract 2
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 2
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 2
229960002930 sirolimus Drugs 0.000 title abstract 2
CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 title 1
229940046044 combinations of antineoplastic agent Drugs 0.000 title 1
229960005277 gemcitabine Drugs 0.000 title 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 title 1
238000002360 preparation method Methods 0.000 title 1
229960000235 temsirolimus Drugs 0.000 title 1
206010028980 Neoplasm Diseases 0.000 abstract 1
230000000340 anti-metabolite Effects 0.000 abstract 1
229940100197 antimetabolite Drugs 0.000 abstract 1
239000002256 antimetabolite Substances 0.000 abstract 1
229940034982 antineoplastic agent Drugs 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
229940124302 mTOR inhibitor Drugs 0.000 abstract 1
239000003628 mammalian target of rapamycin inhibitor Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT02726710T 2001-04-06 2002-04-05 Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil ATE406892T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28238801P	2001-04-06	2001-04-06
US28238501P	2001-04-06	2001-04-06

Publications (1)

Publication Number	Publication Date
ATE406892T1 true ATE406892T1 (de)	2008-09-15

Family

ID=26961412

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02726710T ATE406892T1 (de)	2001-04-06	2002-04-05	Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil

Country Status (21)

Country	Link
EP (1)	EP1385551B1 (de)
JP (1)	JP2004525950A (de)
KR (1)	KR100862178B1 (de)
CN (1)	CN1309421C (de)
AT (1)	ATE406892T1 (de)
AU (1)	AU2007242958A1 (de)
BR (1)	BR0208627A (de)
CA (1)	CA2442849A1 (de)
DE (1)	DE60228699D1 (de)
EA (1)	EA010184B1 (de)
ES (1)	ES2312568T3 (de)
HU (1)	HUP0304093A3 (de)
IL (1)	IL157898A0 (de)
MX (1)	MXPA03009092A (de)
NO (1)	NO20034433L (de)
NZ (1)	NZ540047A (de)
PL (1)	PL363991A1 (de)
PT (1)	PT1385551E (de)
SG (1)	SG152906A1 (de)
SI (1)	SI1385551T1 (de)
WO (1)	WO2002080975A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE419239T1 (de)	2000-10-20	2009-01-15	Eisai R&D Man Co Ltd	Verfahren zur herstellung von 4-phenoxy chinolin derivaten
EP3342411B1 (de)	2001-02-19	2019-08-21	Novartis Pharma AG	Rapamycin-derivat zur behandlung von bauchspeicheldrüsenkrebs
GB0124577D0 (en) *	2001-10-12	2001-12-05	Novartis Forschungsstiftung	Novel methods
JP4547911B2 (ja)	2002-02-01	2010-09-22	アリアド・ファーマシューティカルズ・インコーポレイテッド	リン含有化合物およびその用途
UA83484C2 (uk) *	2003-03-05	2008-07-25	Уайт	Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
CN101337930B (zh)	2003-11-11	2010-09-08	卫材R&D管理有限公司	脲衍生物的制备方法
EP1732583A4 (de) *	2004-02-26	2009-08-12	Penn State Res Found	Kombinationstherapien zur behandlung von neoplasie unter verwendung des opioid-wachstumsfaktor-rezeptors
WO2006027545A2 (en) *	2004-09-10	2006-03-16	Agency For Science, Technology And Research	Method
JP4834553B2 (ja)	2004-09-17	2011-12-14	エーザイ・アール・アンド・ディー・マネジメント株式会社	医薬組成物
ZA200706804B (en)	2005-02-03	2008-10-29	Gen Hospital Corp	Method for treating gefitinib resistant cancer
EP1925676A4 (de)	2005-08-02	2010-11-10	Eisai R&D Man Co Ltd	Testverfahren für die wirkung eines vaskularisierungsinhibitors
KR101354828B1 (ko) *	2005-11-04	2014-02-18	와이어쓰 엘엘씨	ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합
AU2006315512B2 (en) *	2005-11-14	2012-11-01	Ariad Pharmaceuticals, Inc.	Administration of an mTOR inhibitor to treat patients with cancer
GB0523658D0 (en) *	2005-11-21	2005-12-28	Novartis Ag	Organic compounds
NO20220050A1 (no) *	2005-11-21	2008-08-12	Novartis Ag	Neuroendokrin tumorbehandling
EP1880723A1 (de) *	2006-07-14	2008-01-23	Novartis AG	Kombination aus mTOR Inhibitor und Antifolat Verbindung
CA2637069A1 (en) *	2006-01-12	2007-07-19	Novartis Ag	Combination of mtor inhibitor and antipolate compound
WO2007106503A2 (en)	2006-03-13	2007-09-20	Osi Pharmaceuticals, Inc.	Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
WO2007124252A2 (en) *	2006-04-05	2007-11-01	Novartis Ag	Combinations of therapeutic agents for treating cancer
RU2448708C3 (ru)	2006-05-18	2017-09-28	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Противоопухолевое средство против рака щитовидной железы
US20090311249A1 (en) *	2006-06-02	2009-12-17	Luca Gianni	Capecitabine Combination Therapy
EP2054061A4 (de) *	2006-08-02	2009-09-02	Ariad Pharma Inc	Kombinationstherapie
US8865737B2 (en)	2006-08-28	2014-10-21	Eisai R&D Management Co., Ltd.	Antitumor agent for undifferentiated gastric cancer
WO2008044068A2 (en) *	2006-10-11	2008-04-17	Fusion Antibodies Limited	Combination therapy
AU2007319825B2 (en)	2006-11-14	2014-01-23	Ariad Pharmaceuticals, Inc.	Oral formulations
CN101616671A (zh)	2007-01-19	2009-12-30	卫材R&D管理有限公司	胰腺癌治疗用组合物
WO2008093855A1 (ja)	2007-01-29	2008-08-07	Eisai R & D Management Co., Ltd.	未分化型胃癌治療用組成物
KR20150002886A (ko) *	2007-03-07	2015-01-07	아브락시스 바이오사이언스, 엘엘씨	항암제로서 라파마이신 및 알부민을 포함하는 나노입자
AU2008260447B2 (en)	2007-06-01	2013-10-10	Abraxis Bioscience, Llc	Methods and compositions for treating recurrent cancer
US8022216B2 (en)	2007-10-17	2011-09-20	Wyeth Llc	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR101513326B1 (ko)	2007-11-09	2015-04-17	에자이 알앤드디 매니지먼트 가부시키가이샤	혈관 신생 저해 물질과 항종양성 백금 착물의 병용
AU2009225434B2 (en)	2008-03-21	2014-05-22	The University Of Chicago	Treatment with opioid antagonists and mTOR inhibitors
CA2725598C (en)	2008-06-17	2013-10-08	Wyeth Llc	Antineoplastic combinations containing hki-272 and vinorelbine
MX2011001318A (es)	2008-08-04	2011-03-04	Wyeth Llc	Combinaciones antineoplasicas de 4-anilino-3-cianoquinolinas y capecitabina.
EP2416774B1 (de)	2009-04-06	2015-11-04	Wyeth LLC	Behandlungsschema mit neratinib gegen brustkrebs
TH121482A (th)	2009-08-19	2013-02-28	นางสาวปัณณพัฒน์ เหลืองธาตุทอง	องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยอนุพันธ์ของควิโนลีน
AU2011270165B2 (en)	2010-06-25	2015-12-24	Eisai R&D Management Co., Ltd.	Antitumor agent using compounds having kinase inhibitory effect in combination
WO2012144463A1 (ja)	2011-04-18	2012-10-26	エーザイ・アール・アンド・ディー・マネジメント株式会社	腫瘍治療剤
EP3444363B1 (de)	2011-06-03	2020-11-25	Eisai R&D Management Co., Ltd.	Biomarker zur vorhersage und beurteilung des ansprechens von schilddrüsen- und nierenkrebspatienten auf lenvatinibverbindungen
RU2015115397A (ru)	2012-12-21	2017-01-25	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Аморфная форма производного хинолина и способ его получения
ES2687968T3 (es)	2013-05-14	2018-10-30	Eisai R&D Management Co., Ltd.	Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
KR20230043234A (ko)	2014-08-28	2023-03-30	에자이 알앤드디 매니지먼트 가부시키가이샤	고순도의 퀴놀린 유도체 및 이를 제조하는 방법
LT3263106T (lt)	2015-02-25	2024-01-10	Eisai R&D Management Co., Ltd.	Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko)	2015-03-04	2024-05-02	머크 샤프 앤드 돔 코포레이션	암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
MX373231B (es)	2015-06-16	2020-05-08	Eisai R&D Man Co Ltd	Agente anticancerigeno.
CA2994925C (en)	2015-08-20	2023-08-29	Eisai R&D Management Co., Ltd.	Tumor therapeutic agent
AU2017241524B2 (en)	2016-03-28	2021-07-08	Incyte Corporation	Pyrrolotriazine compounds as TAM inhibitors
US12303505B2 (en)	2017-02-08	2025-05-20	Eisai R&D Management Co., Ltd.	Tumor-treating pharmaceutical composition
BR112019023064A2 (pt)	2017-05-16	2020-06-09	Eisai R&D Man Co Ltd	tratamento de carcinoma hepatocelular
TWI821200B (zh)	2017-09-27	2023-11-11	美商英塞特公司	Tam抑制劑之鹽
US11241438B2 (en)	2018-06-29	2022-02-08	Incyte Corporation	Formulations of an AXL/MER inhibitor
EP4114401A1 (de)	2020-03-06	2023-01-11	Incyte Corporation	Kombinationstherapie mit axl/mer- und pd-1/pd-l1-inhibitoren

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE877700A (fr) *	1978-11-03	1980-01-14	Ayerst Mckenna & Harrison	Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US5066493A (en) *	1978-11-03	1991-11-19	American Home Products Corporation	Rapamycin in treatment of tumors
US5362718A (en) *	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
NZ336676A (en) *	1997-01-24	2000-01-28	Norsk Hydro As	Gemcitabine esters or amides useful as anti-cancer and anti-viral agents
TW466112B (en) *	1998-04-14	2001-12-01	Lilly Co Eli	Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same

2002
- 2002-04-05 PL PL02363991A patent/PL363991A1/xx unknown
- 2002-04-05 WO PCT/US2002/010912 patent/WO2002080975A1/en not_active Ceased
- 2002-04-05 NZ NZ540047A patent/NZ540047A/en unknown
- 2002-04-05 EP EP02726710A patent/EP1385551B1/de not_active Expired - Lifetime
- 2002-04-05 SI SI200230737T patent/SI1385551T1/sl unknown
- 2002-04-05 BR BR0208627-1A patent/BR0208627A/pt not_active IP Right Cessation
- 2002-04-05 PT PT02726710T patent/PT1385551E/pt unknown
- 2002-04-05 HU HU0304093A patent/HUP0304093A3/hu unknown
- 2002-04-05 IL IL15789802A patent/IL157898A0/xx unknown
- 2002-04-05 MX MXPA03009092A patent/MXPA03009092A/es active IP Right Grant
- 2002-04-05 CN CNB028077490A patent/CN1309421C/zh not_active Expired - Fee Related
- 2002-04-05 DE DE60228699T patent/DE60228699D1/de not_active Expired - Fee Related
- 2002-04-05 KR KR1020037013090A patent/KR100862178B1/ko not_active Expired - Fee Related
- 2002-04-05 EA EA200301091A patent/EA010184B1/ru not_active IP Right Cessation
- 2002-04-05 AT AT02726710T patent/ATE406892T1/de not_active IP Right Cessation
- 2002-04-05 CA CA002442849A patent/CA2442849A1/en not_active Withdrawn
- 2002-04-05 ES ES02726710T patent/ES2312568T3/es not_active Expired - Lifetime
- 2002-04-05 JP JP2002579013A patent/JP2004525950A/ja active Pending
- 2002-04-05 SG SG200506382-1A patent/SG152906A1/en unknown
2003
- 2003-10-03 NO NO20034433A patent/NO20034433L/no not_active Application Discontinuation
2007
- 2007-12-13 AU AU2007242958A patent/AU2007242958A1/en not_active Withdrawn

Also Published As

Publication number	Publication date
EA010184B1 (ru)	2008-06-30
HK1060062A1 (en)	2004-07-30
CN1545419A (zh)	2004-11-10
CN1309421C (zh)	2007-04-11
HUP0304093A3 (en)	2008-08-28
EP1385551B1 (de)	2008-09-03
EP1385551A1 (de)	2004-02-04
BR0208627A (pt)	2004-03-09
MXPA03009092A (es)	2004-02-12
KR20040007491A (ko)	2004-01-24
SI1385551T1 (sl)	2008-12-31
KR100862178B1 (ko)	2008-10-09
HUP0304093A2 (hu)	2004-04-28
IL157898A0 (en)	2004-03-28
DE60228699D1 (de)	2008-10-16
WO2002080975A1 (en)	2002-10-17
PT1385551E (pt)	2008-11-03
ES2312568T3 (es)	2009-03-01
EA200301091A1 (ru)	2004-02-26
NO20034433D0 (no)	2003-10-03
JP2004525950A (ja)	2004-08-26
CA2442849A1 (en)	2002-10-17
AU2007242958A1 (en)	2008-01-10
NZ540047A (en)	2007-01-26
SG152906A1 (en)	2009-06-29
NO20034433L (no)	2003-11-25
PL363991A1 (en)	2004-11-29

Legal Events

Date

Code

Title

Description

2009-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1385551

Country of ref document: EP

2011-01-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE406892T1 (de)	2008-09-15	Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil
NO20054133L (no)	2005-10-03	Antineoplastiske kombinasjoner omfattende at rapamycin derivat og en aromatase inhibitor
DE60226666D1 (de)	2008-07-03	Wälz- und Gleitlagerbauteil und Wälzlager
BR0211769A (pt)	2004-07-27	Combinações antineoplásicas
ATE414514T1 (de)	2008-12-15	Kombinationen, ein antidiarrhoikum und epothilon oder ein epothilonderivat enthaltend
CY2007019I2 (el)	2017-07-12	Β-αμινο-τετραϋδροϊμιδαζο-(1,2-α)-πυραζινες και τετραϋδροτριαζολο-(4,3-α)-πυραζινες ως αναστολεις της διπεπτιδυλο πεπτιδασης για την αγωγη ή προληψη του διαβητη
NO20052855D0 (no)	2005-06-13	Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav.
DE602004023760D1 (de)	2009-12-03	Kompositstent mit inneren und äusseren stentelementen und anwendungsverfahren
SG148031A1 (en)	2008-12-31	Use of cci-779 as an antineoplastic agent
IS7735A (is)	2005-03-10	Bensódíasepín afleiður og lyfjasamsetningar sem innihalda þær.
CY1109119T1 (el)	2014-07-02	Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης που περιλαμβανουν λαμοτριγινη
DE60328677D1 (de)	2009-09-17	Stent und stent-prothese
EP1513825A4 (de)	2011-01-05	Antituberkulöses arzneimittel: zusammensetzungen und verfahren
BR0301985B1 (pt)	2013-09-24	copolímero de flúor, artigo e laminado
DE50304776D1 (de)	2006-10-05	Bohrlochbehandlungsmittel mit niedrig-toxischer ölphase
BRPI0508451A (pt)	2007-07-24	método de tratamento de linfoma não-hodgkin em um mamìfero, usos de uma combinação de cci-779 e rituximab e de uma combinação de um inibidor de mtor e rituximab, produtos contendo cci-779 e rituximab e um inibidor mtor e rituximab, embalagem farmacêutica, e, composição farmacêutica
EP1476419A4 (de)	2005-03-30	N-biphenylmethylaminocycloalkancarboxamid-derivative
AR033012A1 (es)	2003-12-03	Combinaciones antineoplasicas
EP1512405A4 (de)	2009-11-18	Zusammensetzung zur linderung von chloasma und zusammensetzung zur linderung von stumpfem aussehen
BR0208566B1 (pt)	2013-12-24	Derivados de Beta-Carbolina, Seu Uso, e composição Farmacêutica
ITVR20010031A0 (it)	2001-03-12	Uso di epigallocatechin-3-gallato o suoi derivati nella profilassi e nel trattamento delle malattie neurodegenerative.
ECSP055823A (es)	2005-08-11	DERIVADOS DE [6,7-DIHIDRO-5H-IMIDAZO[1,2-a]IMIDAZOL-3-SULFONILAMINO]-PROPIONAMIDA
EP1578348A4 (de)	2011-03-16	Formulierung mit bioaktiven mitteln und verwendungsverfahren dafür
NO20041484L (no)	2004-04-13	Cisplatinformuleringer med redusert toksisitet og fremgangmater for anvendelse av disse
EP1433187A4 (de)	2007-10-24	Tantalgesinterter körper und kondensator mit dem gesinterten körper